Journal
DRUG DISCOVERY TODAY
Volume 21, Issue 10, Pages 1711-1718Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.07.004
Keywords
-
Categories
Funding
- Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare of Japan
- Ministry of Education, Culture, Sports, Science and Technology of Japan [24390042]
- Adaptable and Seamless Technology Transfer Program through Target-driven R&D, Japan Science and Technology Agency
- Platform for Drug Discovery, Informatics and Structural Life Science of the Ministry of Education, Culture, Sports, Science and Technology, Japan
- Takeda Science Foundation
- Japan Society for the Promotion of Science for Young Scientists
- Grants-in-Aid for Scientific Research [15J10065, 24390042] Funding Source: KAKEN
Ask authors/readers for more resources
Claudins (CLDNs) are a 27-member family of tetra-transmembrane proteins that have pivotal roles in maintaining cellular polarity and sealing the spaces between adjacent cells. Deregulation of their functions is often associated with pathological conditions, including carcinogenesis and inflammation. Some CLDNs are co-receptors for hepatitis C virus. Because CLDN-driven regulation of intercellular seals might be manipulated to enhance drug absorption, CLDNs are attractive targets for drug development. Monoclonal antibodies recognizing the extracellular domain of CLDNs are the first choice for therapeutics, but their development has been delayed. Here, we overview recent advances in the creation of anti-CLDN antibodies and discuss CLDNs as drug development targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
